Does ITI Actually Work in Hemophilia B – RPTH Journal
RPTH Journal shared a post on LinkedIn about a recent article by Shaoyu Yin et al, adding:
“Immune tolerance induction (ITI) in hemophilia B: does it actually work?
This systematic review makes one thing clear: ITI in hemophilia B is unpredictable and risky.
What the data show:
Across 125 patients:
- Success rates vary wildly (from 12.8 pecent to 100 percent)
- Time to tolerance: approximately 1 to 19 months
- Multiple attempts often needed
The real challenge: safety
Adverse events are not rare, they’re defining:
- Allergic reactions: from 0 to 100 percent
- Nephrotic syndrome: from 0 to 33 percent
These complications are far more common than in hemophilia A.
This is the key issue:
- No standardized definition of ‘success.’
- No uniform ITI protocol
- Small, heterogeneous cohorts
We’re comparing apples to oranges across studies.
Clinical insight
- ITI can still work, even after failure or allergic reactions
- But nephrotic syndrome is a major red flag (often treatment-limiting)
- Immunosuppression is widely used but doesn’t eliminate risk
Big picture
Unlike hemophilia A, where ITI is established: Hemophilia B remains a high-risk, low-predictability space
And until we standardize protocols: We’re optimizing therapy without a common playbook.”
Title: Treatment outcomes, safety, and characteristics of immune tolerance induction in patients with hemophilia B and inhibitors: a systematic review
Authors: Shaoyu Yin, Jiahong Wu, Wen Yang, Hongli Mu, Yuexing Peng, Haoran Lu, Rong Li, Hui Bi, Zeping Zhou
Read the Full Article on Research and Practice in Thrombosis and Haemostasis
See more in the gallery.
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 23, 2026, 18:27Advancing Gene Therapy Research for Glanzmann Thrombasthenia – Glanzmann’s Research Foundation
-
Jun 23, 2026, 18:17What Every ITP Patient Wants to Know – ITP Support Association
-
Jun 23, 2026, 18:13Ahsan Fareed: Exploring Heart Failure Readmissions in Iron Deficiency Anemia
-
Jun 23, 2026, 18:09Swarnava Roy: Key Findings on Stress Erythropoiesis and Mitochondrial Retention in RBCs
-
Jun 23, 2026, 17:40Hossam El Benawi: How do We Predict Recurrence Post LVT Resoultion?
-
Jun 23, 2026, 17:39Nicolas Gendron: Do We Really Need All These Hemostasis Tests in Patients on DOACs?
-
Jun 23, 2026, 17:33Maité Mulkers: Time is Brain, and One Reason is That a Thrombus Develops Over Time
-
Jun 23, 2026, 17:32Dhargam Aljebouri: Honoured to Be Part of the Young Professionals Breakfast at ISBT 2026
-
Jun 23, 2026, 17:27Dianne E. van der Wal: Phenotype and Activation of the Endothelium in ET at ISTH 2026